46 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
% of the then issued and outstanding common shares of the Company.
The fair value of stock options granted was estimated on the date of grant using the Black … using the Black-Scholes option pricing model with the following data and assumptions:
Dividend yield
Nil
Annualized volatility
Share price
CAD $3.10
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
or some of the limitations, contraindications, warnings or precautions included in the reference product’s label, including a black box warning, or may … .
The Company uses the Black-Scholes option pricing model to estimate fair value at each period end date. The key assumptions used in the model are described
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
was estimated at $185,738 on the date of grant using the Black-Scholes option pricing model with the following assumptions: expected life of 5.0 years … the Black-Scholes model with the following data and assumptions:
Dividend yield
Nil
Annualized volatility
Risk-free interest rate
Expected life
5
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
% of the then issued and outstanding common shares of the Company.
The fair value of stock options granted was estimated on the date of grant using the Black … using the Black-Scholes option pricing model with the following data and assumptions:
Dividend yield
Nil
Annualized volatility
Share price
CAD $3.10
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:11pm
or some of the limitations, contraindications, warnings or precautions included in the reference product’s label, including a black box warning … .
The Company uses the Black-Scholes option pricing model to estimate fair value at each period end date. The key assumptions used in the model
424B3
t054oijtqnd733r1fb4e
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.1
43oq9pacol06y ggceur
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-99.1
jy2ov6sbfrzx
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
424B3
5amyl
25 Aug 23
Prospectus supplement
6:00am
424B3
ifk5umywesodi7iaq
25 Aug 23
Prospectus supplement
6:00am
6-K
EX-99.1
dtpxw
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
6-K
EX-99.2
ga4hr8qkuk4 27
30 May 23
Notice of Annual & Special Meeting of Shareholders
7:00am
6-K
EX-99.1
bd12n3bi9vszntjon
16 May 23
Condensed Interim Consolidated Financial Statements
9:32am
6-K
EX-99.3
zaximlwmib1n125nnr8
3 Apr 23
Consolidated Financial Statements
6:05am
6-K
EX-99.1
g3nwabwq8gica9mh
3 Apr 23
Consolidated Financial Statements
6:05am
424B3
sw1g8 bd4
14 Nov 22
Prospectus supplement
1:51pm
6-K
EX-99.1
tq2n tfbnfkhmr
14 Nov 22
Condensed Interim Consolidated Financial Statements
1:04pm
S-8
EX-4.2
xyviah b1075r4ft
27 Oct 22
Registration of securities for employees
7:09pm